This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/520631-ema-blood-condition-astrazeneca-vaccine/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| EU drug regulator reviewing 5 cases of NEW blood condition in AstraZeneca Covid vaccine recipients amid possible link to jab | EU drug regulator reviewing 5 cases of NEW blood condition in AstraZeneca Covid vaccine recipients amid possible link to jab |
| (5 months later) | |
| Five cases of a very rare blood disorder in people who have received the Covid-19 vaccine developed by AstraZeneca are being reviewed by the European Medicines Agency (EMA), the EU's drug regulator has said. | Five cases of a very rare blood disorder in people who have received the Covid-19 vaccine developed by AstraZeneca are being reviewed by the European Medicines Agency (EMA), the EU's drug regulator has said. |
| The cases of "capillary leak syndrome," which can cause leakage of fluid from blood vessels, tissue swelling and a drop in blood pressure, were reported from across the European Economic Area, the EMA said on Friday. | The cases of "capillary leak syndrome," which can cause leakage of fluid from blood vessels, tissue swelling and a drop in blood pressure, were reported from across the European Economic Area, the EMA said on Friday. |
| The regulator said it is "not yet clear" if there is a causal association between AstraZeneca's Vaxzevria jab and the condition, which can cause organ failure if it is not treated. | The regulator said it is "not yet clear" if there is a causal association between AstraZeneca's Vaxzevria jab and the condition, which can cause organ failure if it is not treated. |
| The EMA said the five cases, all reported in the European Economic Area, warrant further investigation and potentially an update to the vaccine's product information, if deemed necessary by its Pharmacovigilance Risk Assessment Committee (PRAC). | The EMA said the five cases, all reported in the European Economic Area, warrant further investigation and potentially an update to the vaccine's product information, if deemed necessary by its Pharmacovigilance Risk Assessment Committee (PRAC). |
| The reports of capillary leak syndrome are the latest blow for AstraZeneca's vaccine after the EMA said this week that "unusual blood clots with low blood platelets" should be listed as very rare side effects of the jab. | The reports of capillary leak syndrome are the latest blow for AstraZeneca's vaccine after the EMA said this week that "unusual blood clots with low blood platelets" should be listed as very rare side effects of the jab. |
| The results of a PRAC review into blood clots prompted a number of countries to limit the Anglo-Swedish vaccine to older people only, due to most cases of blood clotting occurring in the under-60s. | The results of a PRAC review into blood clots prompted a number of countries to limit the Anglo-Swedish vaccine to older people only, due to most cases of blood clotting occurring in the under-60s. |
| On Friday, Greece announced it was limiting the vaccine to people aged 30 and older, becoming the latest European state to slap age limits on the jab in recent days after Spain, Italy, Portugal, the Netherlands and UK. | On Friday, Greece announced it was limiting the vaccine to people aged 30 and older, becoming the latest European state to slap age limits on the jab in recent days after Spain, Italy, Portugal, the Netherlands and UK. |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |